NASDAQ:TOCATocagen Stock Price, Forecast & News

Tocagen's stock was trading at $1.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TOCA stock has increased by 871.0% and is now trading at $15.05. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Tocagen.

Tocagen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tocagen.

Tocagen Inc (NASDAQ:TOCA) announced its quarterly earnings results on Thursday, April, 23rd. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.01. Tocagen had a negative net margin of 176,433.34% and a negative return on equity of 327.74%. View Tocagen's earnings history.

7 analysts have issued twelve-month target prices for Tocagen's shares. Their forecasts range from $1.00 to $3.32. On average, they anticipate Tocagen's share price to reach $1.77 in the next year. This suggests that the stock has a possible downside of 88.2%. View analysts' price targets for Tocagen.

News stories about TOCA stock have been trending very negative this week, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tocagen earned a media sentiment score of -3.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Tocagen.

Some companies that are related to Tocagen include Passage Bio (ZNTL), Heron Therapeutics (HRTX), Portola Pharmaceuticals (PTLA), Revance Therapeutics (RVNC), ZEALAND PHARMA/S (ZEAL), Esperion Therapeutics (ESPR), Karyopharm Therapeutics (KPTI), Amneal Pharmaceuticals (AMRX), Theravance Biopharma (TBPH), Innoviva (INVA), Arvinas (ARVN), Kiniksa Pharmaceuticals (KNSA), Akcea Therapeutics (AKCA), Tricida (TCDA) and Supernus Pharmaceuticals (SUPN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tocagen investors own include Inovio Pharmaceuticals (INO), Selecta Biosciences (SELB), Amarin (AMRN), VBI Vaccines (VBIV), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), Protalix Biotherapeutics (PLX), Agile Therapeutics (AGRX) and Catalyst Pharmaceuticals (CPRX).

(TOCA) raised $80 million in an initial public offering (IPO) on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel served as the underwriters for the IPO.

Tocagen trades on the NASDAQ under the ticker symbol "TOCA."

Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TOCA stock can currently be purchased for approximately $15.05.

Tocagen has a market capitalization of $359.98 million and generates $40,000.00 in revenue each year. The company earns $-63,520,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Tocagen employs 77 workers across the globe.

The official website for Tocagen is www.tocagen.com.

Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected]